Literature DB >> 23639506

Immune circuits in asthma.

Stephen T Holgate1.   

Abstract

Asthma is an inflammatory disorder of the conducting airways that has traditionally been classified according to severity. While this has been helpful in guiding treatment with drugs that are currently available such as β2-adrenoceptor agonists and corticosteroids, it takes little account of disease heterogeneity and causal pathways. This review draws attention to subphenotypes of asthma involving different mechanisms and moves the focus away from the adaptive immune response more towards innate immune mechanisms. This mandates a new view of the disease in which causal pathways linked to biomarkers are found and treatments targeted to these pathways as described in a more personalised approach to medicine.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23639506     DOI: 10.1016/j.coph.2013.03.008

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  3 in total

Review 1.  The expanding role of immunopharmacology: IUPHAR Review 16.

Authors:  Ekaterini Tiligada; Masaru Ishii; Carlo Riccardi; Michael Spedding; Hans-Uwe Simon; Mauro Martins Teixeira; Mario Landys Chovel Cuervo; Stephen T Holgate; Francesca Levi-Schaffer
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

2.  Prevalence of IgE-mediated allergy and evaluation of Th1/Th2 cytokine profiles in patients with severe bronchial asthma.

Authors:  Barbara Rogala; Andrzej Bozek; Joanna Gluck; Jerzy Jarzab
Journal:  Postepy Dermatol Alergol       Date:  2015-08-12       Impact factor: 1.837

3.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Loki zupa in Patients With Chronic Asthma.

Authors:  Yubao Lv; Ying Wei; Muhammadjan Abduwaki; Tohti Jurat; Fengsen Li; Huaizhen Wang; Yuhua Wu; Zheng Li; Bo Liu; Hongjun Yin; Yuxue Cao; Mammat Nurahmat; Zihui Tang; Jingcheng Dong
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.